Xen Capital

Xen Capital is an alternative investment platform enabling accredited investors access and liquidity in top-tier investment opportunities. Most accredited investors in Asia are locked out of alternative opportunities due to high barriers to entry – high minimum investment levels, zero liquidity, and lack of transparency. Only a small fraction of investors have access to the above-market returns and performance of alternative investments, including private equity, venture capital, real estate, infrastructure, private debt, and hedge funds.

Xen creates a fintech solution which allows fractionalized access and tradability in alternative investments, through a user-friendly, compliant onboarding platform.

Xen is opening up an industry, traditionally dominated by and designed for UHNWIs and institutional investors, to accredited investors seeking access and liquidity in alternatives.

Founded in 2018 by a strong management team of former investment bankers, traders and fintech veterans, Xen envisions a future of alternative asset management powered by technology for the utmost transparency, liquidity and cost-efficiency.

Xen Capital, established in 2018 and headquartered in Asia., specializes in investments across Biotechnology, InsurTech, Health Care, Wellness, Genetics, Health Diagnostics, Financial Services, Finance, Business Development, Angel Investment. The organization boasts a portfolio of 1 investments, with an average round size of $120.0M and 1 successful exits. Their recent investments include Prenetics, Aspex Management, PAG. The highest investment round they participated in was $5.8B. Among their most notable exits are Prenetics and Aspex Management. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.